References
- Schneider B, Zienkiewicz T, Jansen V, Hofmann T, Noltenius H, Meinertz T. Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy findings. Am J Cardiol. 1996;77:1202–1209.
- Meissner I, Khandheria BK, Heit JA, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47:440–445. doi:10.1016/j.jacc.2005.10.044.
- Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17–20.
- Mazzucco S, Li L, Binney L, Rothwell PM, Cohort OVSP. Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis. Lancet Neurol. 2018;17:609–617. doi:10.1016/S1474-4422(18)30167-4.
- Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148–1152. doi:10.1056/NEJM198805053181802.
- Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083–1091. doi:10.1056/NEJMoa1211716.
- Furlan AJ, Reisman M, Massaro J, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–999. doi:10.1056/NEJMoa1009639.
- Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011–1021. doi:10.1056/NEJMoa1705915.
- Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033–1042. doi:10.1056/NEJMoa1707404.
- Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022–1032. doi:10.1056/NEJMoa1610057.
- Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol. 2018;71:2335–2342. doi:10.1016/j.jacc.2018.02.046.
- Anantha Narayanan M, Vakil K, Reddy YN, et al. Efficacy of implantable cardioverter-defibrillator therapy in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis of randomized controlled trials. JACC Clin Electrophysiol. 2017;3:962–970. doi:10.1016/j.jacep.2017.02.006.
- Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111. doi:10.1002/jrsm.12.
- Saver JL, Mattle HP, Thaler D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke: a topical review. Stroke. 2018;49:1541–1548. doi:10.1161/STROKEAHA.117.018153.
- Madhkour R, Meier B. Patent foramen ovale closure, a contemporary review. Struct Heart. 2018;2:114–120. doi:10.1080/24748706.2017.1420274.
- Mojadidi MK, Mahmoud AN, Patel NK, Elgendy IY, Meier B. Cryptogenic stroke and patent foramen ovale: ready for prime time? J Am Coll Cardiol. 2018;72:1183–1185. doi:10.1016/j.jacc.2018.03.549.
- Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 food and drug administration circulatory system devices panel meeting on patent foramen ovale closure devices. Circulation. 2007;116:677–682. doi:10.1161/CIRCULATIONAHA.107.709972.
- Messé SR, Gronseth G, Kent DM, et al. Practice advisory: recurrent stroke with patent foramen ovale (update of practice parameter): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2016;87:815–821. doi:10.1212/WNL.0000000000002961.
- Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–1100. doi:10.1056/NEJMoa1301440.
- Rengifo-Moreno P, Palacios IF, Junpaparp P, Witzke CF, Morris DL, Romero-Corral A. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2013;34:3342–3352. doi:10.1093/eurheartj/eht285.
- Kent DM, Dahabreh IJ, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials. J Am Coll Cardiol. 2016;67:907–917. doi:10.1016/j.jacc.2015.12.023.
- Chen X, Chen SD, Dong Y, Dong Q. Patent foramen ovale closure for patients with cryptogenic stroke: a systematic review and comprehensive meta-analysis of 5 randomized controlled trials and 14 observational studies. CNS Neurosci Ther. 2018;24:853–862. doi:10.1111/cns.12980.
- Ando T, Holmes AA, Pahuja M, et al. Meta-analysis comparing patent foramen ovale closure versus medical therapy to prevent recurrent cryptogenic stroke. Am J Cardiol. 2018;121:649–655. doi:10.1016/j.amjcard.2017.11.037.
- Mojadidi MK, Elgendy AY, Elgendy IY, Mahmoud AN, Meier B. Atrial fibrillation after percutaneous patent foramen ovale closure. Am J Cardiol. 2018;122:915. doi:10.1016/j.amjcard.2018.05.035.
- Meier B, Nietlispach F. The evil of the patent foramen ovale: we are seeing but the tip of the iceberg. Eur Heart J. 2018;39:1650–1652. doi:10.1093/eurheartj/ehy134.